Indicaciones actuales de tratamiento triple para la hepatitis C

Autor:	Javier Fernández Castroagudín, J. Enrique Domínguez Muñoz, Esther Molina Pérez
Rok vydání:	2012
Předmět:	medicine.medical_specialty Cirrhosis Hepatology business.industry Ribavirin Gastroenterology medicine.disease Virus Telaprevir chemistry.chemical_compound Regimen chemistry Pegylated interferon Boceprevir Internal medicine medicine Adverse effect business medicine.drug
Zdroj:	RUNA. Repositorio da Consellería de Sanidade e Sergas Servizo Galego de Saúde (SERGAS)
ISSN:	0210-5705
DOI:	10.1016/j.gastrohep.2012.01.003
Popis:	Chronic hepatitis C virus (HCV) infection is the main cause of liver cirrhosis and liver carcinoma in western countries. There is evidence that HCV clearance induced by antiviral therapy is beneficial, increasing survival and reducing the complications of cirrhosis. Triple therapy with boceprevir or telaprevir associated with pegylated interferon and ribavirin has increased rates of sustained viral response both in treatment-naive patients and in those failing previous regimens. Before treating patients with these new molecules, physicians should be familiar with their indications and the regimens to be used. Furthermore, both adverse events and the development of resistances must be monitored. The main aims are careful selection of patients and of the regimen to be used, and achieving adequate adherence to obtain optimal results.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cabc45794f9d38147f341f9e05aedfd2 https://doi.org/10.1016/j.gastrohep.2012.01.003 Zobrazit plný text záznamu